Pfizer

lyme disease tick forest
Biotech

Pfizer, Valneva miss Lyme shot ph. 3 goal but plan approval push

Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its key goal.
James Waldron Mar 23, 2026 6:45am
Prune

Pfizer drops another early cancer candidate from Seagen

Mar 19, 2026 12:56pm
New York City St Patricks Day

J&J changes New York state of mind, closing JLABS site

Mar 17, 2026 11:20am
gold arrow pointing upward forward

Pfizer's hotly tipped breast cancer prospect records phase 2 win

Mar 17, 2026 8:40am
One extinguished candle on dark background

Biotech unit Pfizer Ignite flames out

Mar 12, 2026 3:58pm
target reach ladder climb meet win beat competition

Pfizer ramps up plans for trispecific after ph. 2 eczema win

Mar 9, 2026 9:10am